following a full submission:
elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil (as fumarate) film coated tablet (Stribild®) is accepted for use within NHS Scotland.
Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.
Stribild® was at least as effective as two other recommended antiretroviral regimens in treatment-naïve HIV-1 infected patients.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Stribild®. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice182KB (PDF)
Medicine details
- Medicine name:
- elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg film coated tablet (Stribild®)
- SMC ID:
- 887/13
- Indication:
- For treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 August 2013